Serum uric acid concentration as non-classic cardiovascular risk factor in women with polycystic ovary syndrome: Effect of treatment with ethinyl-estradiol plus cyproterone acetate versus metformin

Human Reproduction

Volumn 23, Issue 7, 2008, Pages 1594-1601

  Luque Ramírez, Manuel ^a,b,c   Álvarez Blasco, Francisco ^a,b   Uriol Rivera, Miguel Giovanni ^a,b,d   Escobar Morreale, Héctor F ^a,b  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^d HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

Author keywords

Clinical trial; Hyperandrogenemia; Insulin resistance; Metformin; Obesity

Indexed keywords

DIANE; METFORMIN; URIC ACID;

ADOLESCENT; ADULT; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HUMAN; OBESITY; OVARY POLYCYSTIC DISEASE; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; URIC ACID BLOOD LEVEL;

EID: 44949239546     PISSN: 02681161     EISSN: 14602350     Source Type: Journal    
DOI: 10.1093/humrep/den095     Document Type: Article

References (53)

1. Adamopoulos D, Vlassopoulos C, Seitanides B, Contoyiannis P, Vassilopoulos P. The relationship of sex steroids to uric acid levels in plasma and urine. Acta Endocrinol (Copenh) 1977;85:198-208.
2. Alderman MH. Uric acid and cardiovascular risk. Curr Opin Pharmacol 2002;2:126-130.
3. Anttila L, Rouru J, Penttilä T, Irjala K. Normal serum acid concentrations in women with polycystic ovary syndrome. Hum Reprod 1996;11:2405-2407.
4. Asuncion M, Calvo RM, San Millan JL, Sancho J, Avila S, Escobar-Morreale HF. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J Clin Endocrinol Metab 2000;85:2434-2438.
5. Athyros VG, Elisaf M, Papageorgiou AA, Symeonidis AN, Pehlivanidis AN, Boulokus VI, Milionis HJ, Mikhailidis DP, Group GSC. Effects of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: a subgroup analysis of the GREek Atorvastatin and Coronary-heart- disease Evaluation (GREACE) study. Am J Kidney Dis 2004;43:589- 599.
6. Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 2004;89:2745-2749.
7. Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, Janssen OE, Legro RS, Norman RJ, Taylor AE et al. Position statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J Clin Endocrinol Metab 2006;91:4237-4245.
8. Baker JF, Krishnan E, Chen L, Schumacher HR. Serum uric acid and cardiovascular disease: recent developments, and where do they leave us? Am J Med 2005;118:816-826.
9. Brand FN, McGee DL, Kannel WB, Stokes J, 3rd, Castelli WP. Hyperuricemia as a risk factor of coronary heart disease: The Framingham Study. Am J Epidemiol 1985;121:11-18.
10. Clausen JO, Borch-Johnsen K, Ibsen H, Pedersen O. Analysis of the relationship between fasting serum uric acid and the insulin sensitivity index in a population-based sample of 380 young healthy Caucasians. Eur J Endocrinol 1998;138:63-69.
11. Culleton BF, Larson MG, Kannel WB, Levy D. Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. Ann Intern Med 1999;131:7-13.
12. Diamanti-Kandarakis E, Kouli CR, Bergiele AT, Filandra FA, Tsianateli TC, Spina GG, Zapanti ED, Bartzis MI. A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. J Clin Endocrinol Metab 1999;84:4006-4011.
13. Diamanti-Kandarakis E, Baillargeon J-P, Iuorno MJ, Jakubowicz DJ, Nestler JE. A modern medical quandary: polycystic ovary syndrome, insulin resistance, and oral contraceptive pills. J Clin Endocrinol Metab 2003;88:1927-1932.
14. Ehrmann DA. Polycystic ovary syndrome. N Engl J Med 2005;352:1223-1236.
15. Ehrmann DA, Cavaghan MK, Barnes RB, Imperial J, Rosenfield RL. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care 1999;22:141-146.
16. Escobar-Morreale HF, San Millan JL. Abdominal adiposity and the polycystic ovary syndrome. Trends Endocrinol Metab 2007;18:266- 272.
17. Escobar-Morreale HF, Serrano-Gotarredona J, Garcia-Robles R, Sancho J, Varela C. Mild adrenal and ovarian steroidogenic abnormalities in hirsute women without hyperandrogenemia: does idiopathic hirsutism exist? Metabolism 1997;46:902-907.
18. Escobar-Morreale HF, Lasunción MA, Sancho J. Treatment of hirsutism with ethinyl estradiol-desogestrel contraceptive pills has beneficial effects on the lipid profile and improves insulin sensitivity. Fertil Steril 2000a;74:816-819.
19. Escobar-Morreale HF, Avila S, Sancho J. Serum prostate-specific antigen concentrations are not useful for monitoring the treatment of hirsutism with oral contraceptive pills. J Clin Endocrinol Metab 2000b;85:2488- 2492.
20. Escobar-Morreale HF, Villuendas G, Botella-Carretero JI, Sancho J, San Millan JL. Obesity, and not insulin resistance, is the major determinant of serum inflammatory cardiovascular risk markers in pre-menopausal women. Diabetologia 2003;46:625-633.
21. Fang J, Alderman MH. Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971-1992. National Health and Nutrition Examination Survey. JAMA 2000;283:2404-2410.
22. Farquharson CA, Butler R, Hill A, Belch JJ, Struthers AD. Allopurinol improves endothelial dysfunction in chronic heart failure. Circulation 2002;106:221-226.
23. Goodman A. Terminology and evaluation of abnormal uterine bleeding in premenopausal women. In: Rose BD (ed). UpToDate. Waltham, MA: UpToDate, Inc, 2007.
24. Hatch R, Rosenfield RL, Kim MH, Tredway D. Hirsutism: implications, etiology, and management. Am J Obstet Gynecol 1981;140:815-830.
25. Hayden MR, Tyagi SC. Uric acid: A new look at an old risk marker for cardiovascular disease, metabolic syndrome and type 2 diabetes mellitus: The urate redox shuttle. Nutr Metab (Lond) 2004;1:10.
26. Hoieggen A, Alderman MH, Kjeldsen SE, Julius S, Devereux RB, De Faire U, Fyhrquist F, Ibsen H, Kristianson K, Lederballe-Pedersen O et al. The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int 2004;66:1714-1715.
27. Johnson RJ, Kang DH, Feig D, Kivlighn S, Kanellis J, Watanabe S, Tuttle KR, Rodriguez-Iturbe B, Herrera-Acosta J, Mazzali M. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension 2003;41:1183-1190.
28. Kanellis J, Kang DH. Uric acid as a mediator of endothelial dysfunction, inflammation, and vascular disease. Semin Nephrol 2005;25:39-42.
29. Legro RS. Polycystic ovary syndrome and cardiovascular disease: a premature association? Endocr Rev 2003;24:302-312.
30. Legro RS, Kunselman AR, Dunaif A. Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome. Am J Med 2001;111:607-613.
31. Liese AD, Hense HW, Löwel H, Döring A, Tietze M, Keil U. Association of serum uric acid with all-cause and cardiovascular disease mortality and incident myocardial infarction in the MONICA Augsburg cohort. World Health Organization Monitoring Trends and Determinants in Cardiovascular Diseases. Epidemiology 1999;10:391-397.
32. Luque-Ramírez M, Alvarez-Blasco F, Mendieta-Azcona C, Botella-Carretero JI, Escobar-Morreale HF. Obesity is the major determinant of the abnormalities in blood pressure found in young women with the polycystic ovary syndrome. J Clin Endocrinol Metab 2007a;92:2141-2148.
33. Luque-Ramírez M, Alvarez-Blasco F, Botella-Carretero JI, Martinez-Bermejo E, Lasunción MA, Escobar-Morreale HF. Comparison of ethinyl-estradiol plus cyproterone acetate versus metformin effects on classic metabolic cardiovascular risk factors in women with the polycystic ovary syndrome. J Clin Endocrinol Metab 2007b;92:2453-2461.
34. Luque-Ramírez M, Alvarez-Blasco F, Botella-Carretero JI, Sanchon R, San Millan JL, Escobar-Morreale HF. The increased body iron stores of obese women with polycystic ovary syndrome are a consequence of insulin resistance and hyperinsulinism, and do not result from reduced menstrual losses. Diabetes Care 2007c;30:2309-2313.
35. Mantzoros CS, Georgadis EI, Young R, Evagelopoulou C, Khoury S, Katsilambros N, Sowers JR. Relative androgenicity, blood pressure levels, and cardiovascular risk factors in young healthy women. Am J Hypertens 1995;8:606-614.
36. Marinello E, Leoncini R, Terzouli L, Vannoni D, Porcelli B, Resconi G. Effect of testosterone on purine nucleotide metabolism in rat liver. Horm Metab Res 2004;36:614-619.
37. Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 1999;22:1462-1470.
38. Mercuro G, Vitale C, Cerquetani E, Zoncu S, Deidda M, Fini M, Rosano GM. Effect of hyperuricemia upon endothelial function in patients at increased cardiovascular risk. Am J Cardiol 2004;94:932-935.
39. Moriarity JT, Folsom AR, Iribarren C, Nieto FJ, Rosamond WD. Serum uric acid and risk of coronary heart disease: Atherosclerosis Risk in Communities (ARIC) Study. Ann Epidemiol 2000;10:136-143.
40. Nicholls A, Scott JT. Effect of weight-loss on plasma and urinary levels of uric acid. Lancet 1972;2:1223-1224.
41. Niskanen LK, Laaksonen DE, Nyyssonen K, Alfthan G, Lakka HM, Salonen JT. Uric acid level as a risk factor for cardiovascular and all-cause mortality in middle-aged men: a prospective cohort study. Arch Intern Med 2004;164:1546-1551.
42. Quiñones Galvan A, Natali A, Baldi S, Frascerra S, Sanna G, Ciociaro D, Ferrannini E. Effect of insulin on uric acid excretion in humans. Am J Physiol 1995;268:E1-E5.
43. Quiñonez Zarza C, Silva Ruiz R, Torres Juárez JM. Obesity, arterial hypertension, metabolic disorders, and polycystic ovary syndrome. Ginecol Obstet Mex 2000;68:317-322.
44. Scott JT, Sturge RA. The effect of weight loss on plasma and urinary uric acid and lipid levels. Adv Exp Med Biol 1977;76B:274-277.
45. Struthers AD, Donnan PT, Lindsay P, McNaughton D, Broomhall J, MacDonald TM. Effect of allopurinol on mortality and hospitalisations in chronic heart failure: a retrospective cohort study. Heart 2002;87:229-234.
46. Tai MM. A mathematicalmodel for the determination of total area under glucose tolerance and other metabolic curves. Diabetes Care 1994;17:152-154.
47. The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004;19:41-47.
48. Vizzotto L, Vartemati M, Marinello E, Leoncini R, Pagani R, Pizzichini M. Effect of testosterone on purine metabolism and morphometric parameters in the rat liver. Mol Cell Endocrinol 1996;119:123-127.
49. Weimert NA, Tanke WF, Sims JJ. Allopurinol as a cardioprotective during coronary artery bypass graft surgery. Ann Pharmacother 2003;37:1708-1711.
50. Wild RA. Polycystic ovary syndrome: a risk for coronary artery disease? Am J Obstet Gynecol 2002;186:35-43.
51. Wild S, Pierpoint T, Jacobs H, McKeigue P. Long-term consequences of polycystic ovary syndrome: results of a 31 year follow-up study. Hum Fertil (Camb) 2000;3:101-105.
52. Yarali H, Yildirir A, Aybar F, Kabakçi G, Bükülmez O, Akgül E, Oto A. Diastolic dysfunction and increased serum homocysteine concentrations may contribute to increased cardiovascular risk in patients with polycystic ovary syndrome. Fertil Steril 2001;76:511-516.
53. Zawadzki JK, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In: Dunaif A, Givens JR, Haseltine FP, Merriam GR (eds). Polycystic Ovary Syndrome. Boston: Blackwell Scientific Publications, 1992, 377-384.